Multidrug-resistant tuberculosis--can the tide be turned?

Lancet Infect Dis. 2001 Oct;1(3):199-202. doi: 10.1016/s1473-3099(01)00096-2.

Abstract

Despite continued control efforts, tuberculosis remains a leading cause of illness and death worldwide, with more cases today than at any previous time in history. Not only is there a global increase in the disease itself, there is a worrying rise in the number of cases resistant to the two principal antituberculosis drugs, isoniazid and rifampicin--so called multidrug resistance.

Publication types

  • Review

MeSH terms

  • Antitubercular Agents / therapeutic use
  • Drug Resistance, Bacterial
  • Global Health*
  • Humans
  • Isoniazid / therapeutic use
  • Rifampin / therapeutic use
  • Tuberculosis, Multidrug-Resistant / drug therapy
  • Tuberculosis, Multidrug-Resistant / economics
  • Tuberculosis, Multidrug-Resistant / epidemiology
  • Tuberculosis, Multidrug-Resistant / prevention & control*

Substances

  • Antitubercular Agents
  • Isoniazid
  • Rifampin